Kymera Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 9 | -$2.80 | -$0.10 | -$0.72 |
| Q2 2024 | 4 | -$2.65 | -$0.09 | -$0.68 |
| Q3 2024 | 8 | -$3.23 | -$0.11 | -$0.83 |
| Q4 2024 | 14 | -$1.12 | -$0.11 | -$0.77 |
| Q1 2025 | 6 | -$0.95 | -$0.66 | -$0.84 |
| Q2 2025 | 5 | -$3.39 | -$0.12 | -$0.87 |
| Q3 2025 | 5 | -$3.31 | -$0.11 | -$0.85 |
| Q4 2025 | 5 | -$3.87 | -$0.13 | -$1.00 |
Kymera Therapeutics, Inc. Earnings Date And Information
Kymera Therapeutics, Inc. last posted its earnings results on Thursday, October 31st, 2024. The company reported $-0.82 earnings per share for the quarter, topping analysts' consensus estimates of $-0.83 by $0.01. The company had revenue of 3.74 M for the quarter and had revenue of 78.59 M for the year. Kymera Therapeutics, Inc. has generated $-3 earnings per share over the last year ($-2.52 diluted earnings per share) and currently has a price-to-earnings ratio of -21.68. Kymera Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 20th, 2025 based on prior year's report dates.
Kymera Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 10/31/2024 | Q3 2024 | -$0.83 | -$0.82 | 0.01 | $10.34 M | $3.74 M |
| 08/07/2024 | Q2 2024 | -$0.69 | -$0.58 | 0.11 | $12.55 M | $25.65 M |
| 05/02/2024 | Q1 2024 | -$0.73 | -$0.69 | 0.04 | $10.29 M | |
| 02/22/2024 | Q4 2023 | -$0.44 | -$0.25 | 0.19 | $47.89 M | |
| 11/02/2023 | Q3 2023 | -$0.73 | -$0.90 | -0.17 | $15.97 M | $4.73 M |
| 08/03/2023 | Q2 2023 | -$0.70 | -$0.67 | 0.03 | $14.06 M | $16.51 M |
| 05/04/2023 | Q1 2023 | -$0.69 | -$0.63 | 0.06 | $9.47 M | |
| 02/23/2023 | Q4 2022 | -$0.57 | -$0.59 | -0.02 | $16.14 M | |
| 11/03/2022 | Q3 2022 | -$0.70 | -$0.79 | -0.09 | $15.51 M | $9.55 M |
| 08/09/2022 | Q2 2022 | -$0.68 | -$0.77 | -0.09 | $14.24 M | $11.51 M |
| 05/03/2022 | Q1 2022 | -$0.67 | -$0.71 | -0.04 | $9.62 M | |
| 02/24/2022 | Q4 2021 | -$0.36 | -$0.66 | -0.3 | $15.28 M | |
| 11/10/2021 | Q3 2021 | -$0.34 | -$0.56 | -0.22 | $19.61 M | $20.34 M |
| 08/06/2021 | Q2 2021 | -$0.21 | -$0.55 | -0.34 | $18.81 M | $18.52 M |
| 05/06/2021 | Q1 2021 | -$0.17 | -$0.29 | -0.12 | $18.70 M | |
| 03/11/2021 | Q4 2020 | $0.09 | -$0.29 | -0.38 | $12.79 M | |
| 11/05/2020 | Q3 2020 | -$0.18 | $84.00 M | $14.53 M | ||
| 06/29/2020 | Q2 2020 | -$0.32 | $3.29 M | |||
| 03/30/2020 | Q1 2020 | -$0.25 | $3.43 M | |||
| 12/30/2019 | Q4 2019 | -$0.26 | $1.83 M |
Kymera Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Kymera Therapeutics, Inc.'s earnings date?
Kymera Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 20th, 2025 based off last year's report dates.
-
Did Kymera Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Kymera Therapeutics, Inc. (:KYMR) reported $-0.82 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.83 by $0.01.
-
How can I listen to Kymera Therapeutics, Inc.'s earnings conference call?
The conference call for Kymera Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Kymera Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Kymera Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Kymera Therapeutics, Inc. generate each year?
Kymera Therapeutics, Inc. (:KYMR) has a recorded annual revenue of $78.59 M.
-
How much profit does Kymera Therapeutics, Inc. generate each year?
Kymera Therapeutics, Inc. (:KYMR) has a recorded net income of $78.59 M. Kymera Therapeutics, Inc. has generated $-2.52 earnings per share over the last four quarters.
-
What is Kymera Therapeutics, Inc.'s price-to-earnings ratio?
Kymera Therapeutics, Inc. (:KYMR) has a price-to-earnings ratio of -21.68 and price/earnings-to-growth ratio is -0.58.
